arabinofuranosyluracil has been researched along with Hepatitis B Virus Infection in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 19 (63.33) | 18.2507 |
| 2000's | 7 (23.33) | 29.6817 |
| 2010's | 4 (13.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, JY; Kim, NH; Koh, MS; Lee, JH; Park, KS; Park, SH | 1 |
| Kim, HS; Park, SA; Shin, YI; Yang, CY | 1 |
| Shouval, D | 1 |
| Byun, KS; Cho, M; Cho, SH; Chon, CY; Chung, YH; Han, BH; Han, CJ; Han, JY; Hwang, JS; Hwang, SG; Kim, BI; Kim, HC; Kim, JH; Kim, TH; Kim, YS; Koh, KC; Lee, HJ; Lee, HS; Lee, KS; Lee, MS; Lee, YS; Paik, SW; Ryu, SH; Um, SH; Yang, JM; Yoo, BC; Yoo, HW; Yoo, K | 1 |
| Abdelhamed, AM; Furman, PA; Isom, HC; Kelley, CM; Miller, TG | 1 |
| Chevallier, M; Guerret, S; Jacquard, AC; Jamard, C; Nassal, M; Peyrol, S; Pichoud, C; Ren, S; Rimsky, LT; Schultz, U; Trepo, C; Werle, B; Zoulim, F | 1 |
| Buti, M; Esteban, R | 1 |
| Kang, MJ; Kim, DH; Lee, HS; Lee, J; Yoo, BC; Yoo, HH; Yoo, HW | 1 |
| Byun, KS; Cho, M; Cho, SH; Choi, JY; Choi, SK; Chon, CY; Chung, YH; Han, BH; Han, JY; Hwang, JS; Hwang, SG; Jeong, SH; Kim, BI; Kim, DG; Kim, HC; Kim, JH; Kim, TH; Kim, YS; Kweon, YO; Lee, HJ; Lee, HS; Lee, HY; Lee, KS; Lee, MS; Lee, YJ; Lee, YS; Paik, SW; Park, JW; Ryu, SH; Um, SH; Yang, JM; Yoo, BC; Yoo, HW; Yoo, K | 1 |
| Conjeevaram, H; Di Bisceglie, AM; Fried, MW; Kleiner, D; Luciano, C; McKenzie, R; Park, Y; Sallie, R; Savarese, B; Tsokos, M | 1 |
| Swartz, MN | 1 |
| de Man, RA; Heijtink, RA; Niesters, HG; Schalm, SW | 2 |
| Caldwell, SH; Dickson, RC; Ishitani, MB; McGory, RW; Oliveira, WM; Pruett, TL; Stevenson, WC | 1 |
| Caldwell, S; Dickson, R; Gaffey, M; Ishitani, M; Lobo, P; McCullough, C; Pruett, T; Stevenson, W | 1 |
| Brahams, D | 1 |
| Marwick, C | 1 |
| Marshall, E | 1 |
| Macilwain, C | 1 |
| Bari, A | 1 |
| Lewis, W; Perrino, FW | 1 |
| Gordon, M | 1 |
| Colacino, JM | 1 |
| Ascenzi, MA; de Courten-Myers, G; Engelman, L; Gerin, JL; Griniuviene, B; Hornbuckle, WE; Levine, ES; Lewis, W; Montione, R; Tankersley, KO; Tennant, BC | 1 |
| Gaffey, MJ; Hoofnagle, JH; Kleiner, DE; McKenzie, R; Nichols, L; Sallie, R; Straus, SE; Tsokos, M | 1 |
| de Man, RA; Honkoop, P; Schalm, SW; Scholte, HR | 1 |
| Ascenzi, MA; Baldwin, BH; Bowsher, RR; Colacino, JM; Cote, PJ; Engelhardt, JA; Erb, HN; Gerin, JL; Graham, LA; Hornbuckle, WE; Korba, BE; Lewis, W; Lopez, C; Richardson, FC; Rowland, PH; Tennant, BC; Tochkov, IA; Yeager, AE | 1 |
| Miller, JP; Mintz, PD | 1 |
| Kocic, I | 1 |
| Boyer, N; Castelneau, C; Marcellin, P | 1 |
7 review(s) available for arabinofuranosyluracil and Hepatitis B Virus Infection
| Article | Year |
|---|---|
Drugs in development for hepatitis B.
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Emtricitabine; Guanine; Hepatitis B; Humans; Interferon alpha-2; Interferon-alpha; Nucleosides; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2005 |
New nucleoside analogues for chronic hepatitis B.
Topics: 2-Aminopurine; Antiviral Agents; Arabinofuranosyluracil; Chronic Disease; Drug Evaluation, Preclinical; Famciclovir; Hepatitis B; Humans; Lamivudine; Nucleosides; Zalcitabine | 1995 |
New developments in antiviral therapy for chronic hepatitis B infection.
Topics: 2-Aminopurine; Antiviral Agents; Arabinofuranosyluracil; Clinical Trials as Topic; Famciclovir; Hepatitis B; Hepatitis, Chronic; Humans; Interferon-alpha; Lamivudine; Treatment Outcome; Zalcitabine | 1995 |
Mechanisms for the anti-hepatitis B virus activity and mitochondrial toxicity of fialuridine (FIAU).
Topics: Animals; Antiviral Agents; Arabinofuranosyluracil; DNA, Mitochondrial; Electron Transport Complex IV; Hepatitis B; Hepatitis B virus; Humans; Liver | 1996 |
Mitochondrial injury. Lessons from the fialuridine trial.
Topics: Antiviral Agents; Arabinofuranosyluracil; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; DNA-Directed DNA Polymerase; Hepatitis B; Hepatitis B virus; Humans; Liver; Mitochondria; Oxidation-Reduction; Pyruvates; Risk Assessment; Structure-Activity Relationship | 1997 |
Clevudine University of Georgia/Abbott/Bukwang/Triangle/Yale University.
Topics: Animals; Antiviral Agents; Arabinofuranosyluracil; Clinical Trials as Topic; Contraindications; Drugs, Investigational; Epstein-Barr Virus Infections; Hepatitis B; Humans; Structure-Activity Relationship | 2000 |
[New management strategies for hepatitis B].
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Emtricitabine; Guanine; Hepatitis B; Humans; Lamivudine; Organophosphonates | 2002 |
4 trial(s) available for arabinofuranosyluracil and Hepatitis B Virus Infection
| Article | Year |
|---|---|
Rapid quantitative determination of L-FMAU-TP from human peripheral-blood mononuclear cells of hepatitis B virus-infected patients treated with L-FMAU by ion-pairing, reverse-phase, liquid chromatography/electrospray tandem mass spectrometry.
Topics: Adult; Antiviral Agents; Arabinofuranosylcytosine Triphosphate; Arabinofuranosyluracil; Chromatography, High Pressure Liquid; Half-Life; Hepatitis B; Humans; Mass Spectrometry; Middle Aged; Reproducibility of Results | 2006 |
Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B.
Topics: Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Arabinofuranosyluracil; Double-Blind Method; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Placebos | 2007 |
Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.
Topics: Acidosis, Lactic; Adult; Alanine Transaminase; Antiviral Agents; Arabinofuranosyluracil; Chronic Disease; DNA, Mitochondrial; DNA, Viral; Drugs, Investigational; Female; Hepatitis B; Humans; Jaundice; Liver; Liver Failure; Liver Transplantation; Male; Middle Aged; Pancreatitis; Peripheral Nervous System Diseases | 1995 |
Deaths in US fialuridine trial.
Topics: Acidosis, Lactic; Acquired Immunodeficiency Syndrome; Animals; Antiviral Agents; Arabinofuranosyluracil; Cause of Death; Chronic Disease; Female; Hepatitis B; Humans; Male; Middle Aged; Survival Rate | 1994 |
19 other study(ies) available for arabinofuranosyluracil and Hepatitis B Virus Infection
| Article | Year |
|---|---|
Clevudine Induced Mitochondrial Myopathy.
Topics: Adult; Aged; Antiviral Agents; Arabinofuranosyluracil; Creatine Kinase; Databases, Factual; Electromyography; Female; Hepatitis B; Humans; L-Lactate Dehydrogenase; Lower Extremity; Male; Middle Aged; Mitochondrial Myopathies; Muscle, Skeletal; Neck | 2017 |
Polymyositis in patients taking antiviral clevudine therapy: a report of two cases.
Topics: Adult; Antiviral Agents; Arabinofuranosyluracil; Creatine Kinase; Female; Hepatitis B; Humans; Male; Middle Aged; Polymyositis | 2010 |
Focus.
Topics: Albumins; Antiviral Agents; Arabinofuranosyluracil; Cholangitis, Sclerosing; Cholestasis; Dialysis Solutions; Gastrointestinal Neoplasms; Hepatitis B; Humans; Incidence; Muscular Diseases; Pruritus; Renal Dialysis; Risk Factors | 2010 |
Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy.
Topics: Alanine Transaminase; Antiviral Agents; Arabinofuranosyluracil; DNA, Viral; Follow-Up Studies; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Viral Load | 2011 |
Rebound of hepatitis B virus replication in HepG2 cells after cessation of antiviral treatment.
Topics: Antiviral Agents; Arabinofuranosyluracil; Baculoviridae; Cell Line; DNA, Viral; Hepatitis B; Hepatitis B virus; Humans; Kinetics; Lamivudine; Recombination, Genetic; Virus Replication | 2002 |
Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection.
Topics: Adenoviridae; Animals; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; DNA-Directed DNA Polymerase; Drug Combinations; Emtricitabine; Genetic Therapy; Hepatitis B; Hepatitis B Core Antigens; Hepatitis B Virus, Woodchuck; Interferon-gamma; Liver; Marmota; Microscopy, Confocal; Microscopy, Electron; Mitochondria, Liver; Proliferating Cell Nuclear Antigen; Recombinant Proteins; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Viremia; Virus Replication | 2004 |
Mitochondrial toxicity--new adverse drug effects.
Topics: Antiviral Agents; Arabinofuranosyluracil; Chronic Disease; Clinical Trials as Topic; DNA, Mitochondrial; Hepatitis B; Humans; Liver Failure | 1995 |
Effects of fialuridine on hepatitis B immune globulin pharmacokinetics following orthotopic liver transplant for chronic hepatitis B viral-induced cirrhosis.
Topics: Adult; Antiviral Agents; Arabinofuranosyluracil; DNA, Viral; Female; Hepatitis B; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunoglobulins, Intravenous; Liver Cirrhosis; Liver Transplantation; Male | 1995 |
Clinical course of four patients receiving the experimental antiviral agent fialuridine for the treatment of chronic hepatitis B infection.
Topics: Antiviral Agents; Arabinofuranosyluracil; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Hepatitis B; Humans; Lactates; Liver Transplantation; Randomized Controlled Trials as Topic | 1995 |
NIH panel report of 'no flaws' in FIAU trial at variance with FDA report, new probe planned.
Topics: Antiviral Agents; Arabinofuranosyluracil; Cause of Death; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Hepatitis B; Hepatitis, Chronic; Humans; Liver Diseases; National Institutes of Health (U.S.); Scientific Misconduct; United States; United States Food and Drug Administration | 1994 |
Hepatitis study. Drug trial deaths deemed unavoidable.
Topics: Antiviral Agents; Arabinofuranosyluracil; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Federal Government; Government Regulation; Hepatitis B; Humans; National Institutes of Health (U.S.); Pancreatic Diseases; Research Subjects; United States; United States Food and Drug Administration | 1994 |
NIH, FDA seek lessons from hepatitis B drug trial deaths.
Topics: Antiviral Agents; Arabinofuranosyluracil; Hepatitis B; Humans; National Institutes of Health (U.S.); United States; United States Food and Drug Administration | 1993 |
Severe toxicity of fialuridine (FIAU)
Topics: Antiviral Agents; Arabinofuranosyluracil; Chronic Disease; Hepatitis B; Humans; Interferons; Nucleosides | 1996 |
Severe toxicity of fialuridine (FIAU)
Topics: Antiviral Agents; Arabinofuranosyluracil; DNA Polymerase III; DNA, Mitochondrial; Drug Evaluation, Preclinical; Hepatitis B; Humans; In Vitro Techniques | 1996 |
Severe toxicity of fialuridine (FIAU)
Topics: Antiviral Agents; Arabinofuranosyluracil; Chronic Disease; Cytarabine; Drug Approval; Hepatitis B; Humans | 1996 |
Depletion of mitochondrial DNA, destruction of mitochondria, and accumulation of lipid droplets result from fialuridine treatment in woodchucks (Marmota monax).
Topics: Animals; Antiviral Agents; Arabinofuranosyluracil; DNA Damage; DNA, Mitochondrial; Heart; Hepatitis B; Hepatitis B Virus, Woodchuck; Kidney; Lipids; Liver; Marmota; Mitochondria; Mitochondria, Muscle; Muscle, Skeletal; Myocardium | 1997 |
Histopathologic changes associated with fialuridine hepatotoxicity.
Topics: Adult; Antiviral Agents; Arabinofuranosyluracil; Chemical and Drug Induced Liver Injury; Chronic Disease; Clinical Trials, Phase II as Topic; Female; Hepatitis B; Humans; Liver; Male; Middle Aged; Randomized Controlled Trials as Topic | 1997 |
Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection.
Topics: Animals; Anorexia; Antiviral Agents; Arabinofuranosyluracil; Carrier State; DNA, Viral; Hepatitis B; Hepatitis B Core Antigens; Hepatitis B virus; Liver; Marmota; Muscles; Sleep Stages; Time Factors; Virus Replication | 1998 |
Falsely low calcium measurements after high volume plasma exchange in a patient with liver failure.
Topics: Acidosis, Lactic; Anticoagulants; Antiviral Agents; Arabinofuranosyluracil; Calcium; Citrates; Citric Acid; Hepatitis B; Hepatorenal Syndrome; Humans; Liver Failure; Liver Transplantation; Male; Middle Aged; Plasma Exchange; Predictive Value of Tests; Spectrophotometry, Atomic | 1994 |